title: Epidemiologic and clinical data linking factors XI and XII to thrombosis.
abstract: Currently available evidence supports the contention that elevated levels of factor XI (fXI) are associated with a greater risk of venous thromboembolism and ischemic stroke, but, less convincingly, with myocardial infarction. Conversely, reduced plasma levels of fXI seem to offer some protection from venous thromboembolism and stroke, but not myocardial infarction. Factor XI-deficient patients are at risk for certain types of bleeding, particularly posttraumatic hemorrhage on mucosal surfaces where there is a high endogenous fibrinolytic activity. In contrast, the situation with fXII in human thrombosis remains enigmatic. Deficiency of fXII is clearly not associated with any bleeding risk, but neither does it seem to be protective against thrombosis. The longstanding debate as to whether partial fXII deficiency represents a risk factor for thrombosis remains unresolved, with seemingly conflicting results depending on study design, type of assay used, and analyte evaluated. The possibility that elevated fXII levels represent a risk factor for thrombosis is not borne out in the literature.
authors.affiliation: Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Nigel S
authors.initials: NS
authors.lastname: Key
mesh_terms: D000818:Animals; D001777:Blood Coagulation; D004195:Disease Models, Animal; D005172:Factor XI / Q000378:metabolism*; D005174:Factor XII / Q000378:metabolism*; D006801:Humans; D015398:Signal Transduction; D013927:Thrombosis / Q000453:epidemiology* / Q000378:metabolism*
chemical_list: D005174:Factor XII; D005172:Factor XI